Core Viewpoint - PDS Biotechnology Corporation is making significant progress in its clinical programs and financial management, with a focus on accelerating the approval process for its lead immunotherapy product, PDS0101, targeting HPV16-positive head and neck cancer [2][3]. Clinical and Corporate Update - The company amended the VERSATILE-003 Phase 3 clinical trial protocol to include progression-free survival (PFS) as an interim primary endpoint, which is expected to shorten trial duration and reduce costs while maintaining median overall survival as the primary endpoint for full FDA approval [9]. - PDS0101 is positioned as a promising treatment option for patients with HPV16-positive head and neck cancer, addressing a significant unmet medical need [3]. - Early results from the NCI-led trial of PDS01ADC showed a median PFS of 9.6 months and a median PSA decline of 40% in patients with metastatic castration-resistant prostate cancer [9]. Financial Results - For the year ended December 31, 2025, the net loss was approximately $34.5 million, or $0.74 per share, a decrease from a net loss of $37.6 million, or $1.03 per share in 2024 [6][20]. - Research and development expenses decreased to $19.0 million from $22.6 million in 2024, primarily due to reduced manufacturing and personnel costs [7]. - General and administrative expenses also decreased to $12.5 million from $13.8 million in 2024, mainly due to lower personnel costs [8]. - Total operating expenses for 2025 were $31.5 million, down from $36.3 million in 2024 [10][20]. - The company's cash balance as of December 31, 2025, was $26.7 million, down from $41.7 million in 2024 [19].

Core Viewpoint - PDS Biotechnology Corporation is set to host a conference call and webcast on March 30, 2026, to report its financial results for the year ended December 31, 2025, and provide updates on clinical programs and corporate developments [1]. Group 1: Conference Call Details - The conference call is scheduled for March 30, 2026, at 8:00 a.m. Eastern Time [2]. - Dial-in numbers include 1-877-704-4453 for domestic calls and 1-201-389-0920 for international calls [2]. - The event will be archived on PDS Biotech's website for six months following the live webcast [2]. Group 2: Company Overview - PDS Biotechnology is a late-stage immunotherapy company focused on enhancing the immune system's ability to target and eliminate cancers [3]. - The company has initiated a pivotal clinical trial for its lead program targeting advanced HPV16-positive head and neck squamous cell cancers [3]. - PDS0101, the lead investigational targeted immunotherapy, is being developed in combination with a standard immune checkpoint inhibitor and in a triple combination with PDS01ADC, an IL-12 fused antibody drug conjugate [3].

Core Viewpoint - PDS Biotechnology Corporation has amended its Phase 3 VERSATILE-003 clinical trial protocol to include progression-free survival (PFS) as an interim primary endpoint, which may facilitate an accelerated approval pathway for PDS0101 in treating HPV16-positive recurrent and/or metastatic head and neck cancer [1][2]. Group 1: Clinical Trial Details - The amendment allows for a potentially shorter duration of the VERSATILE-003 trial and aims to accelerate the timeline for regulatory submission while enhancing cost efficiency [2]. - The primary endpoint for full approval remains median overall survival (mOS), consistent with prior communications with the U.S. Food and Drug Administration (FDA) [1]. - The FDA did not object to the amended protocol during the standard 30-day wait period following the filing of the Investigational New Drug (IND) Application [1]. Group 2: Company Overview - PDS Biotechnology is a late-stage immunotherapy company focused on innovative cancer treatments, particularly targeting how the immune system can effectively kill cancer cells [3]. - The company's lead investigational product, PDS0101 (Versamune® HPV), is being developed in combination with a standard immune checkpoint inhibitor and a triple combination that includes PDS01ADC, an IL-12 fused antibody drug conjugate [3].

Core Insights - The study led by the National Cancer Institute (NCI) demonstrated a median progression-free survival (PFS) of 9.6 months for the investigational drug PDS01ADC in patients with metastatic castration-resistant prostate cancer (mCRPC) [1][2] - The combination therapy showed a median PSA decline of 40%, with 6 out of 16 patients achieving more than a 50% decline [2] - PDS Biotech aims to advance PDS01ADC as a key component of its immuno-oncology pipeline, reinforcing its potential to enhance existing therapies across various solid tumor types [3] Company Overview - PDS Biotechnology Corporation is a late-stage immunotherapy company focused on transforming immune responses to cancer [4] - The company has initiated a pivotal clinical trial for its lead program targeting advanced HPV16-positive head and neck squamous cell cancers [4] - PDS Biotech's lead investigational therapy, PDS0101 (Versamune HPV), is being developed in combination with standard immune checkpoint inhibitors and PDS01ADC [4]

Core Viewpoint - PDS Biotechnology Corporation has received a Notice of Allowance for its lead asset PDS0101, enhancing its intellectual property estate and providing significant market protections for over 20 years due to the new patent and anticipated biologics exclusivity [1][3]. Intellectual Property and Patent Details - The new patent (U.S. Application No. 16/210,750) is titled "Methods and Compositions Comprising Cationic Lipids for Stimulating Type I Interferon Genes" and will grant broad composition and method of use claims [2]. - This patent strengthens the company's existing intellectual property portfolio, which includes patents granted in major markets such as the U.S., Europe, Japan, China, Australia, Canada, Israel, Mexico, and Hong Kong [2]. Clinical Development and Market Position - PDS0101 is currently in the Phase 3 VERSATILE-003 clinical trial for HPV16-positive head and neck cancers, with a protocol amendment submitted to the FDA to change the progression-free survival endpoint to a primary endpoint for earlier evaluation [3]. - The company is well-positioned to advance its immunotherapy, with the potential for approximately twenty years of market exclusivity for PDS0101 [3]. Company Overview - PDS Biotechnology is focused on transforming cancer treatment through immunotherapy, specifically targeting HPV16-positive head and neck squamous cell cancers [4]. - The lead investigational product PDS0101 (Versamune HPV) is being developed in combination with standard-of-care immune checkpoint inhibitors and other therapies [4].

Core Viewpoint - PDS Biotechnology Corporation has received a new patent in Japan for PDS0101, enhancing its intellectual property portfolio and providing market exclusivity for the product into the 2040s [2][4]. Group 1: Patent and Intellectual Property - The Japan Patent Office has issued Patent No. 7783866 for PDS0101, granting broad composition of matter and methods of use claims [2]. - This new patent expands previously granted patents in Japan and adds to the company's existing patents in the United States, China, Australia, and Hong Kong [2]. - The company has additional patent applications pending in several other countries, reinforcing its global intellectual property position [4][5]. Group 2: Market Context and Product Development - The incidence of HPV16-related cancers is rapidly increasing in the US and Europe, which highlights the potential market for PDS0101 [3]. - PDS0101 is currently being studied in a Phase 3 trial in combination with pembrolizumab for HPV16-positive recurrent/metastatic head and neck cancer [3][6]. - The company aims to advance broad intellectual property protections for PDS0101 and its other investigational agents in development [5].

Core Viewpoint - PDS Biotechnology Corporation is seeking an accelerated approval pathway for its investigational treatment PDS0101 in HPV16-positive recurrent and/or metastatic Head and Neck Cancer, following positive results from the VERSATILE-002 trial [2][3] Group 1: FDA Meeting and Approval Pathway - The FDA has accepted PDS Biotechnology's request for a Type C Meeting to discuss the proposed accelerated approval pathway for PDS0101 [1] - The proposed amendment to the VERSATILE-003 Phase 3 trial aims to change the progression-free survival (PFS) endpoint to a surrogate primary endpoint, allowing for earlier evaluation with significant statistical power [2] - Median overall survival (mOS) will remain the primary endpoint for full approval as originally recommended by the FDA [2] Group 2: Clinical Trial Insights - The VERSATILE-002 trial demonstrated promising median overall survival and durable progression-free survival in patients with CPS ≥ 1 [2] - The company believes that the positive PFS data from VERSATILE-002 presents an opportunity to shorten the duration to a primary endpoint and potentially accelerate regulatory submission [3] Group 3: Company Overview - PDS Biotechnology is a late-stage immunotherapy company focused on transforming immune system responses to cancer [4] - The lead investigational treatment, PDS0101 (Versamune HPV), is being developed in combination with a standard-of-care immune checkpoint inhibitor and in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate [4]

Financial Data and Key Metrics Changes - The company reported a net loss of $9 million or $0.19 per basic and diluted share for Q3 2025, compared to a net loss of $10.7 million or $0.29 per basic share in the prior year's quarter, indicating a decrease in net loss primarily due to lower operating expenses [15][16] - Research and development expenses were $4.6 million for Q3 2025, down from $6.8 million in the prior year, attributed to lower manufacturing and clinical expenses [16] - General and administrative expenses increased to $3.6 million in Q3 2025 from $3.4 million in the prior year, mainly due to higher professional fees [16] - Total operating expenses were $8.1 million for Q3 2025, down from $10.2 million in the prior year [17] - Cash balance as of September 30, 2025, was $26.2 million, down from $41.7 million at the beginning of the year [17] Business Line Data and Key Metrics Changes - The VERSATILE-002 trial showed a median overall survival of 39.3 months for patients with a combined positive score (CPS) of greater than or equal to one, with a progression-free survival (PFS) of 6.3 months among these patients [5][6] - The company plans to amend the VERSATILE-003 trial to include PFS as a primary endpoint alongside median overall survival, based on the strong data from VERSATILE-002 [8][9] Market Data and Key Metrics Changes - The company highlighted that HPV-positive head and neck cancer is becoming a significant medical issue, with over 90% of HPV-positive oropharyngeal cancers being HPV-16 positive [11][30] - Recent market research indicates a growing incidence of HPV-positive head and neck cancer, with traditional causes like tobacco and alcohol declining [30] Company Strategy and Development Direction - The company is focusing on HPV-16 positive head and neck cancer, believing it will become the dominant type of head and neck cancer in the next decade [30][31] - The company is engaging with the FDA to discuss amendments to the VERSATILE-003 trial protocol, aiming to potentially shorten the time to regulatory submission while maintaining median overall survival as an endpoint for full approval [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of PDS0101 as a well-tolerated treatment option for HPV-16 positive patients, who currently lack effective therapies [11][30] - The management noted that the industry is recognizing the growing problem of HPV-positive head and neck cancer, which is reflected in recent publications and market research [10][30] Other Important Information - The National Cancer Institute presented new clinical data at the 2025 Society for Immunotherapy of Cancer meeting, validating the scientific basis of the company's immunotherapy platforms [12][13] - The colorectal cancer cohort of the phase two clinical trial with PDS01ADC met criteria for expansion to stage two following positive results [13] Q&A Session Summary Question: How will the company handle patients already enrolled in the VERSATILE-003 trial during the protocol pause? - The company will continue to treat patients already enrolled in the trial and will discuss their incorporation into the trial with the FDA [20][22] Question: What is the expected PFS for the control Keytruda? - The company conservatively assumes that the PFS in the control arm will be around three months, based on previous studies [26][27] Question: How is the company addressing physician training and awareness regarding pseudoprogression in the VERSATILE-003 study? - The company has trained investigators to recognize pseudoprogression and will conduct central reviews of scans to ensure accurate assessments [39][40]

Core Viewpoint - PDS Biotechnology Corporation has completed the VERSATILE-002 Phase 2 trial for PDS0101 in combination with pembrolizumab, showing promising results that lead the company to seek an expedited approval pathway in the ongoing VERSATILE-003 Phase 3 trial [1][2][3]. Clinical Update - The VERSATILE-002 trial demonstrated a median overall survival (mOS) of 39.3 months for patients with CPS ≥ 1, with a 95% confidence interval lower limit of 23.9 months [4]. - Progression-free survival (PFS) was reported at 6.3 months for the same patient group [4]. - The company plans to amend the ongoing VERSATILE-003 trial to potentially reduce its size while maintaining statistical power, with mOS remaining the primary endpoint for full FDA approval [4][3]. Financial Results - For Q3 2025, the company reported a net loss of $9.0 million, or $0.19 per share, a decrease from a net loss of $10.7 million, or $0.29 per share, in Q3 2024 [5][16]. - Research and development expenses were $4.6 million, down from $6.8 million in the same quarter of the previous year, attributed to lower manufacturing and clinical expenses [6][16]. - General and administrative expenses increased to $3.6 million from $3.4 million year-over-year, primarily due to higher professional fees [7][16]. Cash Position - As of September 30, 2025, the company's cash balance was $26.2 million, a decrease from $41.7 million as of December 31, 2024 [8][15]. - The company raised approximately $5.3 million by selling 5,800,000 shares and accompanying warrants on November 12, 2025 [9]. Additional Clinical Developments - The National Cancer Institute presented new clinical data at the 2025 Society for Immunotherapy of Cancer Annual Meeting, highlighting the immunological properties of PDS0101 and PDS01ADC [4]. - Preliminary results from the colorectal cancer cohort of the Phase 2 clinical trial with PDS01ADC met the criteria for expansion to Stage 2, confirming at least 6 of 9 objective responses [4].

Core Viewpoint - PDS Biotechnology Corporation has announced a securities purchase agreement to raise approximately $5.3 million through the sale of 5,800,000 shares of common stock at a price of $0.91 per share, with potential additional proceeds of up to $5.8 million from warrants [1][3] Group 1: Offering Details - The offering includes 5,800,000 shares of common stock or pre-funded warrants, with accompanying warrants to purchase an additional 5,800,000 shares at an exercise price of $1.00 per share [1][3] - The offering is expected to close on or about November 12, 2025, subject to customary closing conditions [1] - Craig-Hallum is acting as the exclusive placement agent for the offering [2] Group 2: Use of Proceeds - The net proceeds from the offering are intended for the continuation of the VERSATILE-003 Phase 3 clinical trial, discussions with the FDA for protocol amendments, and other research and development expenses [3] Group 3: Financial Position - As of September 30, 2025, the company reported approximately $26.2 million in cash and cash equivalents, subject to final adjustments [4] Group 4: Regulatory Compliance - The offering is being made pursuant to a "shelf" registration statement on Form S-3, previously filed with the SEC [5] Group 5: Existing Warrants Amendment - The company will amend existing warrants issued in February 2025, reducing the exercise price from $1.50 to $1.00 per share, effective upon the closing of the offering [6] Group 6: Company Overview - PDS Biotechnology is a late-stage immunotherapy company focused on transforming immune responses to target and kill cancers, with a pivotal clinical trial for its lead program in advanced HPV16-positive head and neck squamous cell cancers [8][9]